CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 target
Drug / intervention
Milrinone +1 moredrug
Likely dose
Milrinone 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00819377
NCT00819377Phase 2Completed
CompareCT.gov

2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB

Andre Denault·interventional·Posted Jan 9, 2009·Updated Oct 25, 2013

In Brief

A Phase 2 clinical trial evaluating Milrinone and Normal saline for Valvular Stenosis and 3 related conditions. Completed, enrolled 124 participants across 1 site.

Detailed Summary

Pulmonary hypertension is an important morbidity factor in patients having to undergo cardiac surgery with cardiopulmonary bypass (ECC). Milrinone used in inhalation, shows evidence of being a pulmonary vasodilator able to possibly contribute to the reduction of pressure on the pulmonary artery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsValvular Stenosis, Valvular Insufficiency, Hypertension, Pulmonary, Coronary Artery Disease
CountriesCanada
CollaboratorsHeart and stoke fondation of Quebec, Organon, Canadian Anesthesiologists' Society

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.5 years ago

Interventions

Milrinonedrug

inhaled milrinone 5 mg (as for the injectable solution)

Normal salinedrug

5 ml normal saline by inhalation over 15 min